Volpara Health Technologies Limited (ASX: VHT) is under the healthcare sector and the company develops digital health solutions to enable personalized breast cancer screening software applications. The companyâs stock traded at a current market price of $0.860 and the stock initially saw a daily price change of $0.010 and a percentage change of 1.163% as at August 07, 2018 before trading flat. The stock has seen a performance change of 50.88% over the past 12 months. The company has seen a successful completion of share purchase plan and an oversubscribed placement. The cash on hand at end of Q1 FY19 is NZ $22.8 million. The company has recorded quarterly sales performance of adding NZ $4.5 million up by 180% on Q1 FY18 in terms of total contract value. Annual recurring revenue is now $4.46 million which is up by 25% from the end of FY18, targeting NZ $9 million by end FY19. An additional 0.5% added in Q1, now covers 3.7% of women in US with a 9% target for the end of FY19. In April and May, capital raising of A$ 20M was followed by the successful capital raise and subsequent share purchase plan. Bringing the total number of SaaS customers to 85, during the June quarter, Volpara signed 28 new customers to the Volpara Enterprise platform. While VHT is a good play to watch, the stock trades at higher levels and can be looked at for a prospective investment opportunity.
Oventus Medical Limited (ASX: OVN) is another health care company into developing oral devices for the therapeutic treatment of breathing disorders. The companyâs stock traded at a current market price of $0.340 and the stock has seen a daily price change of $0.010 and a percentage change of 3.03% as at August 07, 2018. The stock has seen a performance change of -40.5% over this year to date while it rose 10% in last five days. Obstructive sleep Apnoea is an extensive
market and is worth US$3.8 billion globally, growing at a CAGR of 15-20%. This space delivers competitive advantages for half of the current oral appliance and mask market of $3.8 bn per year. Oventus Airway Technology and valve accessories set to disrupt a large and growing market. Recent data shows that over 75% of patients can be treated without the need for CPAP (Continuous Positive Airway Pressure). The company has a strong institutional investor support and balance sheet. While the stock looks interesting in view of market opportunity and products, however, it might be better to wait for some more positive catalysts to understand the investment returns
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a companyâs prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkineâs team of analysts bought you handpicked report for âTop 25 Dividend Stocks For 2018.â
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.Â Kalkinemedia.comÂ and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.